Skip to main content

Rhinoconjunctivitis

4
Pipeline Programs
1
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
3
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Allergopharma
AllergopharmaGermany - Reinbek
4 programs
1
3
AL0704rPPhase 31 trial
Grass pollen specific immunotherapyPhase 31 trial
grass pollen allergen (recombinant)Phase 3
birch pollen allergen extractPhase 21 trial
Active Trials
NCT00818181Completed73Est. Aug 2010
NCT00671268Completed256Est. Mar 2013
NCT01353755Completed195Est. Sep 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AllergopharmaGrass pollen specific immunotherapy
AllergopharmaAL0704rP
Allergopharmabirch pollen allergen extract

Clinical Trials (3)

Total enrollment: 524 patients across 3 trials

NCT01353755AllergopharmaGrass pollen specific immunotherapy

2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma

Start: Oct 2009Est. completion: Sep 2014195 patients
Phase 3Completed
NCT00671268AllergopharmaAL0704rP

Evaluation of Safety and Efficacy of Specific Immunotherapy With Recombinant Major Allergens of Timothy Grass Pollen Adsorbed Onto Aluminium-hydroxide in Patients With IgE-mediated Allergic Rhinoconjunctivitis +/- Controlled Asthma

Start: Mar 2008Est. completion: Mar 2013256 patients
Phase 3Completed
NCT00818181Allergopharmabirch pollen allergen extract

Open Label Safety Study of a Birch Pollen Allergen Extract

Start: Jun 2008Est. completion: Aug 201073 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.